The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that strengthens its leadership in the genomic medicine sector, Vertex Pharmaceuticals has received an expanded indication for its Casgevy therapy to include children as young as two years old. According to reports, this regulatory milestone allows the company to address a broader pediatric patient population with its innovative gene therapy. The expansion is strategically designed to drive long-term revenue growth by capturing the market at an earlier treatment stage.
This expansion comes as Vertex competes with peers like Bluebird Bio, which has previously secured approvals for similar gene therapies; Vertex reported total Q1 2024 revenues of approximately $2.66 billion per previous company earnings filings. Casgevy remains the first commercial therapy to utilize CRISPR technology, providing a competitive edge in a global gene therapy market that continues to see significant investment per market data.
Sign in to access this content
Sign InVRTX shares closed at $496.73 (close June 30, 2026), having reached an intra-day high of $500.99. Investors are now looking toward the U.S. Core PCE Price Index release on June 25, 2026, as a broader market catalyst for biotech stocks, while monitoring technical support levels near the recent low of $489.62.